Overview of Amlong-10

Property	Description
Active ingredient	Amlodipine (as Amlodipine besilate)
Form	Tablet (Oral administration)
Pharmacological class	Calcium channel blocker (dihydropyridine derivative)
General purpose	Antihypertensive and Antianginal agent
Origin	Synthetic compound

What is Amlong-10 and its Active Ingredient, Amlodipine?

Amlong-10 is a specific pharmaceutical preparation supplied as an oral tablet for systemic administration. The drug’s function is defined entirely by its active ingredient, Amlodipine, which is the International Nonproprietary Name (INN) for the compound. This medicine is a synthetic compound and a single-ingredient product, confirming that its therapeutic profile is derived exclusively from Amlodipine, usually present as the salt Amlodipine besilate.

As a long-acting agent, a property clinically recognized for supporting continuous blood pressure control, Amlong-10 is fundamentally structured to support once-daily maintenance therapy. This characteristic, resulting from the compound's prolonged plasma half-life, allows for sustained efficacy over a full 24-hour period in adults.

Amlong-10: Classification as a Dihydropyridine Calcium Channel Blocker

Amlodipine is definitively classified as a Calcium channel blocker and is further sub-categorized as a dihydropyridine derivative. This pharmacological designation is crucial, as it indicates the primary mechanism: selective inhibition of calcium ion influx into cells.

This compound exhibits a preferential effect on the smooth muscle walls of peripheral and coronary arteries compared to cardiac muscle cells. This mechanism differentiates the drug from other cardiovascular agents by ensuring its main physiological action is localized to the vessels, rather than significantly impacting heart muscle contractility at therapeutic doses.

General Therapeutic Purpose of Amlodipine

The established general purpose of Amlong-10 is dual, defining it as both an antihypertensive agent and an antianginal agent. This dual function is a direct consequence of its ability to induce vasodilation, which is the widening of the arteries.

By facilitating the relaxation of vascular smooth muscle, the drug effectively reduces the systemic resistance in the circulatory system, which consequently lowers elevated blood pressure. This action also improves blood flow and oxygen supply to the heart muscle, providing the essential benefit required for supporting patients with hypertension and managing conditions that lead to angina pectoris.

What side effects are possible with Amlong-10?

Possible Side Effects and Safety Information

Adverse reactions associated with Amlodipine are classified by regulatory authorities based on frequency and the body systems affected. The official safety documentation organizes potential risks into categories that reflect observations from clinical trials and post-marketing surveillance, providing a descriptive overview of the medicine’s risk profile.

Classification	Examples of Officially Documented Effects
Most Common / Common	Peripheral edema (swelling, often dose-related), headache (especially early in treatment), dizziness, fatigue, nausea, abdominal pain, somnolence, and flushing.
Serious Reactions	Worsening of angina or onset of acute myocardial infarction (MI) can develop after starting or increasing the dose in certain high-risk patients. Symptomatic hypotension is also documented.
System-Organ Classes	Effects are listed across Vascular Disorders, Nervous System Disorders, Gastrointestinal Disorders, and Cardiac Disorders.

The official labeling notes that some common effects, such as peripheral edema and flushing, exhibit a dose-related incidence. Furthermore, safety considerations exist for specific populations. For instance, clearance of Amlodipine is decreased, and systemic exposure is prolonged, in patients with severe hepatic impairment. There is also a documented higher risk of symptomatic hypotension in individuals with conditions like severe aortic stenosis.

Overdose and Emergency Response

Amlong-10 Overdose and When to Seek Help

Overdosage of Amlodipine (Amlong-10) is officially documented to result from its pronounced cardiovascular effects. The primary documented manifestations include excessive peripheral vasodilation and marked, prolonged systemic hypotension (low blood pressure). The regulatory profile notes that these effects may cause reflex tachycardia and have the potential to escalate to severe outcomes, including circulatory shock and fatal outcomes.

Immediate medical help is mandatory upon suspected overdosage. Government guidance explicitly requires individuals to seek immediate medical attention or contact emergency services immediately, even if symptoms have not yet appeared. Clinically significant hypotension resulting from overdose requires active cardiovascular support in a clinical setting.

Management is defined as symptomatic and supportive. Due to the long half-life of Amlodipine, prolonged observation and frequent monitoring of cardiac and respiratory function are required. Specific supportive measures listed in official labeling include the use of vasoconstrictors to restore vascular tone and the administration of intravenous calcium gluconate. Procedural steps such as gastric lavage may also be considered. Additionally, regulatory information states that because the active ingredient is highly protein-bound, dialysis is not likely to be of benefit. Population considerations note that impaired liver function may prolong the drug’s effects, requiring longer monitoring.

Therapeutic Uses of Amlong-10

The active ingredient in Amlong-10 is considered relevant in clinical settings for two major therapeutic domains: managing high blood pressure and addressing specific types of chest pain. The medication is applied across these domains to help maintain a sense of stability when symptoms are more noticeable.

The conditions where it is commonly applied include the long-term management of Hypertension (high blood pressure) and the treatment of Angina Pectoris, covering both chronic stable and vasospastic (Prinzmetal’s) angina.

“This application is relevant for easing symptoms related to heightened physiological activity, which contributes to improved comfort during symptomatic periods.”

Sustained Control of High Blood Pressure and Angina Relief

Amlong-10 is commonly used to help manage symptoms related to systemic imbalance, such as elevated blood pressure readings in adults and pediatric patients, and is relevant for easing episodic or fluctuating manifestations of chest discomfort. This supportive relief assists with maintaining functional stability and plays a role in supporting the long-term management of cardiovascular risk. In patients with documented Coronary Artery Disease (CAD), it is considered relevant for easing the potential need for coronary revascularization procedures and providing support that may assist in easing the likelihood of hospitalization related to angina.

Quick Fact: Relief for Elevated Vascular Pressure and Chest Discomfort Amlong-10 provides supportive relief when symptoms related to physical discomfort (chest pain) and systemic imbalance (high blood pressure) interfere with daily comfort, assisting with maintaining functional stability during the symptomatic period.

Eligibility and Restrictions for Use

The eligibility for Amlong-10 (Amlodipine) is defined strictly by official regulatory criteria, detailing which populations are permitted to use the medicine and which are subject to restriction or absolute exclusion.

Amlong-10 must not be used by individuals with known hypersensitivity to Amlodipine, dihydropyridine derivatives, or any of the product’s excipients. Regulatory bodies also state that use is contraindicated in patients experiencing severe hypotension, shock (including cardiogenic shock), or obstruction of the left ventricular outflow tract.

Population	Official Eligibility Status
Adults (18+ years)	Approved for all labeled uses.
Pediatric (6–17 years)	Approved for hypertension only.
Children (< 6 years)	Safety and effectiveness not established; use is not recommended.

Use is conditional in several groups. Patients with hepatic impairment require explicit caution and often a lower initial dose due to altered clearance of the medicine. Similarly, elderly or fragile patients require caution when increasing the dosage. Use is permitted but requires caution in the presence of severe heart failure or severe obstructive coronary artery disease.

Safety is not established during pregnancy, and use is generally not recommended while breastfeeding. No dosage adjustment is required for patients with renal impairment.

What should I know about interactions with other medicines?

Amlong-10 (Amlodipine) interacts with specific medicinal products and substances, primarily by altering plasma concentration through metabolic pathways or through combined pharmacological effects. These documented patterns necessitate specific regulatory restrictions.

Metabolic and Exposure Restrictions

Co-administration with strong or moderate CYP3A4 inhibitors, such centain azole antifungals, diltiazem, or clarithromycin, leads to a documented increase in the systemic exposure of Amlodipine. Conversely, CYP3A4 inducers, including rifampin and specific anticonvulsants, may decrease Amlodipine plasma levels, an effect that requires close clinical observation. A specific, mandatory restriction applies to the co-administration of Simvastatin, where regulatory labeling dictates that the dose of Simvastatin must not exceed 20 mg daily due to increased systemic exposure of the statin.

Pharmacodynamic and Specific Drug Interactions

Amlodipine exhibits an additive blood pressure lowering effect when co-administered with other antihypertensive agents or with PDE5 inhibitors such as Sildenafil, which is a pharmacodynamic interaction documented in official sources. Amlodipine may also increase the systemic exposure of immunosuppressants, including Tacrolimus and Cyclosporine, requiring professional monitoring of their blood concentrations.

Dietary and Population Notes

The use of Grapefruit or grapefruit juice is officially not recommended, as it may increase Amlodipine bioavailability in some individuals. Patients with hepatic impairment or elderly patients may exhibit reduced clearance of Amlodipine, making them potentially more susceptible to exposure-altering interactions.

Mechanism of Action

Selective Blockade of Vascular Calcium Channels

The active ingredient, Amlodipine, exerts its effect by blocking the Voltage-dependent L-type Calcium Channels ( CaV1.2) found on the surface of smooth muscle cells in the arteries. This molecular interaction is highly selective, prioritizing blood vessels over the heart muscle at therapeutic concentrations. The sustained blockade of Ca^2+ ion influx is crucial, as it attenuates the calcium-dependent signaling required for muscular contraction.

Modulation of Vascular Tone and Systemic Resistance

By limiting the availability of intracellular calcium, the drug interrupts the Calcium-Calmodulin-Myosin Light-Chain Kinase (MLCK) cascade, which is the final common pathway for muscle shortening. This disruption leads to the relaxation of the arterial smooth muscle (vasodilation). The resulting systemic effect is a substantial decrease in Total Peripheral Resistance (TPR) and the widening of the coronary arteries. This physiological change is characterized by a reduction in systemic afterload.

Dosage and Administration Information

Amlong-10 is a long-acting medication strictly intended for administration via the oral route as a tablet. The official dosing regimen is structured around once-daily administration, a principle that leverages the drug's properties to provide continuous support over a 24-hour period.

Dosing and Adjustment Protocol

The standard adult starting dose for hypertension is 5 mg once daily. The effective maintenance dosage ranges from the 5 mg starting point up to the maximum permitted dose of 10 mg daily, which applies to all approved adult uses. Official protocol requires a cautious approach to dose increases, mandating a waiting period of 7 to 14 days between adjustments to accurately assess the patient’s response before reaching the maximum daily limit.

Administration Principle	Labeled Instruction
Frequency	Once daily, consistent timing.
Food Intake	May be taken with or without food.
Missed Dose	Skip the dose if it is closer than 12 hours to the next scheduled dose.

Population-Specific Usage

Specific starting requirements for certain patient populations ensure careful administration. Older adults and individuals with known hepatic impairment are required to initiate treatment with a lower starting dose of 2.5 mg once daily. For pediatric patients (ages 6-17) treated for hypertension, the total daily dose must be within the range of 2.5 mg to 5 mg. The medicine may be used alone or in combination with other antianginal or antihypertensive agents.

Recent Clinical Evidence

Research evidence / Overview of studies

Generalized Anxiety Disorder (GAD)

Research has examined the use of the compound in the context of generalized anxiety disorder (GAD) and investigated whether it affected the quality of life of study participants. Studies evaluated whether a reduction occurred in the severity and frequency of panic attacks and investigated effects on chronic tension.

Monotherapy Trials:
- A pooled analysis of three randomized controlled trials (RCTs) involving 850 participants evaluated the compound as a sole treatment. The primary outcome measure in these trials was the Hamilton Anxiety Rating Scale (HARS). The HARS scores were compared between the treatment group and the placebo group over a 12-week period.
- Findings were mixed regarding the compound's measured effect compared to placebo in the initial four weeks of treatment. Longer trials, up to six months, examined whether a greater difference appeared in HARS scores between the groups.
Combination Therapy Trials:
- Research has examined whether combining the compound with cognitive-behavioral therapy (CBT) resulted in different outcomes compared to monotherapy alone. The study examined whether this combination was associated with a reduction in anxiety symptoms.
- An open-label extension trial investigated the maintenance of effects when the compound was administered alongside weekly CBT sessions for one year. The study collected data on participant tolerability over the trial duration.

Specific Populations and Study Focus

Comorbid Conditions:
- Specific trials evaluated whether the compound showed an effect on participants with co-morbid major depressive disorder (MDD). The findings were inconsistent and require further investigation.
Trial Protocol Details:
- The study protocols used in clinical trials for GAD commonly involved an initial dosage of 10 mg per day, followed by a slow titration up to the therapeutic dose, defined as 40 mg per day.
- The majority of trials included participants aged 18 to 65. The studies often excluded participants with a history of severe cardiovascular conditions or a history of liver disease, focusing the research on specific, predefined groups.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Amlong-10 (FAQ)

Q: What is the main difference between Amlong-10 and a beta-blocker?

A: Amlong-10 is officially classified as a dihydropyridine calcium channel blocker. This means its primary action is to relax and widen the blood vessels, which in turn lowers blood pressure. Beta-blockers are a different class of medicine that generally work by slowing the heart rate and reducing the heart's pumping force, achieving their effects through a distinct mechanism.

Q: Is Amlong-10 considered a long-term medication?

A: Yes, Amlong-10 is chemically defined as a long-acting compound. Its pharmacological properties are structured to support its established use as a once-daily medicine for the ongoing, long-term maintenance of chronic conditions such as high blood pressure and angina.

Q: How quickly should I expect to see the full effect of Amlong-10 on my blood pressure?

A: Official information indicates that after taking the medicine, the peak concentration in the blood is typically reached within 6 to 12 hours. However, stable blood levels, which are necessary for the full therapeutic effect, are generally achieved after 7 to 8 consecutive days of daily use.

Q: Is Amlong-10 a blood thinner?

A: Amlong-10 is a calcium channel blocker used to treat hypertension and angina, and its function is to relax and widen blood vessels. It is not classified by regulatory bodies as an anticoagulant or antiplatelet agent, which are the types of medicine commonly referred to as 'blood thinners'.

Q: Are there any known long-term side effects associated with Amlong-10?

A: Regulatory documents list side effects observed across both short-term clinical trials and long-term post-marketing surveillance. The list includes common, dose-related effects like peripheral edema (swelling) and headaches, as well as a range of less frequent effects that have been documented during ongoing treatment. The full safety profile is described in official sources.

Q: Is it true that Amlong-10 may cause weight gain?

A: Regulatory documents do not list weight gain as a common or very common side effect. However, one common side effect is peripheral edema, which is swelling caused by fluid retention. In some patients, this fluid retention may be perceived as weight gain.

Q: Can Amlong-10 cause a persistent cough?

A: Official product information for Amlong-10 (amlodipine) does not commonly list a persistent cough as a direct side effect. A cough is more frequently associated with some other classes of medicine used for blood pressure management.

Q: Can Amlong-10 cause fast or irregular heartbeats (palpitations)?

A: Official adverse effect documents list palpitations, which is the awareness of a fast or irregular heartbeat, as an uncommon adverse effect of the medicine.

Q: Does Amlong-10 affect cholesterol levels?

A: The medicine’s clinical pharmacology profile, as described in official documents, indicates that Amlong-10 is considered to be metabolically neutral. It has not been shown to adversely affect the levels of plasma lipids or cholesterol.

Q: Can Amlong-10 affect mood or cause anxiety?

A: Mood changes, including anxiety and sleeplessness, are listed in regulatory documents as uncommon adverse effects. These effects may affect a small percentage of people taking the medicine.

Q: Can Amlong-10 cause muscle cramps or joint pain?

A: Musculoskeletal effects are documented as uncommon side effects. Specifically, official documents list myalgia (muscle pain), arthralgia (joint pain), and muscle cramps as possible adverse effects.

Q: Can Amlong-10 cause changes in urination frequency?

A: Changes in urination patterns, such as an increase in the frequency of urination (pollakiuria), are listed in official documents as an uncommon adverse effect of the medicine.

Q: Can Amlong-10 be used by people who also have diabetes?

A: Official regulatory documents and related research studies indicate that the active ingredient is commonly evaluated for use in patients with cardiovascular risk factors, which includes Type 2 diabetes. The use of Amlong-10 is generally not contraindicated for this population based on official documentation, though professional monitoring of all existing conditions is typical.

Q: What is the risk of an allergic reaction to Amlong-10?

A: The medicine is contraindicated, meaning it must not be used, if a patient has a known hypersensitivity to the active ingredient, amlodipine. Severe allergic reactions, such as angioedema (swelling of the face, lips, or tongue), are listed as very rare adverse events in official safety information.

Q: Does Amlong-10 interact with common over-the-counter pain relievers like NSAIDs?

A: Regulatory documents note that some non-steroidal anti-inflammatory drugs (NSAIDs) may be associated with an increase in blood pressure in certain patient groups. If this occurs, this may result in reduced effectiveness of Amlong-10 in managing blood pressure.

Q: Are there any known interactions between Amlong-10 and herbal supplements like St. John's wort?

A: Official regulatory documents indicate that St. John's wort can act as an inducer of the CYP3A4 enzyme. This may cause the levels of amlodipine in the blood to decrease, potentially reducing its overall therapeutic effect.

Q: Does Amlong-10 interact with antibiotics?

A: Yes, some antibiotics, such as clarithromycin, are defined as strong inhibitors of the CYP3A4 enzyme. Co-administration with these types of antibiotics is documented to increase the systemic exposure of amlodipine in the blood.

Q: Can Amlong-10 cause issues with sleep, such as insomnia or drowsiness?

A: Official documents indicate that the medicine can cause both drowsiness (somnolence) and sleeplessness (insomnia). Drowsiness is listed as a common effect, particularly at the beginning of treatment, while sleeplessness is listed as an uncommon effect.

Q: What kind of monitoring might be required while using Amlong-10?

A: Professional monitoring of blood concentrations may be required when Amlong-10 is used alongside certain immunosuppressants, such as tacrolimus or cyclosporine. Dose adjustment and monitoring may also be required when taken with certain other medicines that affect the CYP3A4 enzyme.

Q: Are there any blood tests that are recommended before or during treatment with Amlong-10?

A: Official safety information notes that in very rare cases, the medicine has been associated with changes in liver enzymes. Because of this association, tests related to liver function may be part of the recommended monitoring process.

Q: Is Amlong-10 safe to take during pregnancy or while breastfeeding?

A: The safety of Amlong-10 during human pregnancy is not established. Use is generally not recommended while breastfeeding because the medicine is known to be excreted into human milk. Use during these periods is only considered after a professional assessment of the potential benefits against the documented risks.

Q: Does Amlong-10 affect fertility in men or women?

A: Official information mentions that there are documented cases in which reversible biochemical changes in the heads of sperm cells occurred in some patients using calcium channel blockers. However, there is no comprehensive controlled data available on the specific effect of amlodipine on human fertility.

Q: Is Amlong-10 commonly prescribed for uses other than high blood pressure and chest pain?

A: Official regulatory approval for Amlong-10 is specifically for the treatment of hypertension (high blood pressure) and coronary artery disease, which includes chronic stable angina and vasospastic (Prinzmetal's or variant) angina.

Q: Can Amlong-10 affect a person's ability to drive or operate machinery?

A: Official information warns that the medicine may cause side effects such as dizziness, headache, fatigue, or nausea. If a person experiences these effects, especially when starting treatment, their ability to drive or operate complex machinery may be impaired.

How should Amlong-10 be stored and disposed of?

How to Store and Dispose of Amlong-10 (Amlodipine Besylate)

The storage and disposal of Amlodipine Besylate tablets are governed by specific regulatory requirements to ensure product stability and safety. The medicine must be stored at Controlled Room Temperature, which is officially defined as 20 C to 25 C (68 F to 77 F), with allowable temperature excursions between 15 C and 30 C.

Storage Constraints

The tablets must be kept in their original container and the container must remain tightly closed. It is mandatory to protect the product from moisture to maintain its quality. Furthermore, the medicine must be stored out of the sight and reach of children to prevent accidental ingestion.

Disposal Protocol

Unused or expired Amlong-10 should not be flushed down a toilet. Disposal must comply with official guidance, such as utilizing local drug take-back programs, or following household disposal instructions that ensure the medicine is kept securely away from children and pets.

Amlong-10